Italia markets closed

Myriad Genetics, Inc. (MYGN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
19,37-0,10 (-0,51%)
In data: 02:17PM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente19,47
Aperto19,67
Denaro19,26 x 100
Lettera19,41 x 100
Min-Max giorno19,05 - 19,74
Intervallo di 52 settimane13,82 - 24,21
Volume186.381
Media Volume645.562
Capitalizzazione1,753B
Beta (5 anni mensile)1,98
Rapporto PE (ttm)N/D
EPS (ttm)-3,18
Prossima data utili07 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A23,91
  • GlobeNewswire

    New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

    SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a nationwide survey revealing breast density and family health history are two misunderstood breast cancer risk factors. The Myriad Genetics Cancer Risk Survey found that nearly half (48%) of the women surveyed do not know what breast density is, and 50% are unsure if breast density has anything to do with breast cancer risk. Wo

  • GlobeNewswire

    Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

    Myriad can conduct prospective clinical trials using Illumina’s TruSight Oncology Comprehensive Investigational Use Only testSALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two key milestones in its strategic partnership with Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, to advance and support clinical research for gene-based, targeted thera

  • GlobeNewswire

    Myriad Genetics Issues 2022 Environmental, Social and Governance Report

    SALT LAKE CITY, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today released its second annual Environmental, Social and Governance report, highlighting key efforts that reflect its commitment to conduct operations as a responsible, equitable and sustainable partner in the healthcare industry. “At Myriad, we understand the important role we play in advancing health equity and social justice,” said Paul Diaz, presiden